TARO PHARMACEUTICAL INDUS(NYSE:TARO) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 5 out of 10 to TARO. TARO was compared to 194 industry peers in the Pharmaceuticals industry. TARO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. TARO has a valuation in line with the averages, but it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

TARO had positive earnings in the past year.

TARO had a positive operating cash flow in the past year.

TARO had positive earnings in 4 of the past 5 years.

Of the past 5 years TARO 4 years had a positive operating cash flow.

1.2 Ratios

TARO has a better Return On Assets (2.49%) than 84.97% of its industry peers.

TARO has a Return On Equity of 3.00%. This is amongst the best in the industry. TARO outperforms 83.94% of its industry peers.

The Return On Invested Capital of TARO (0.79%) is better than 77.20% of its industry peers.

Measured over the past 3 years, the Average Return On Invested Capital for TARO is significantly below the industry average of 44.04%.

		Industry Rank	Sector Rank
ROA	2.49%
ROE	3%
ROIC	0.79%

ROA(3y)2.12%

ROA(5y)0.14%

ROE(3y)2.63%

ROE(5y)-0.64%

ROIC(3y)2.06%

ROIC(5y)3.87%

1.3 Margins

TARO's Profit Margin of 8.55% is amongst the best of the industry. TARO outperforms 86.53% of its industry peers.

In the last couple of years the Profit Margin of TARO has declined.

The Operating Margin of TARO (3.42%) is better than 79.27% of its industry peers.

In the last couple of years the Operating Margin of TARO has declined.

TARO has a Gross Margin of 48.47%. This is in the better half of the industry: TARO outperforms 60.62% of its industry peers.

TARO's Gross Margin has declined in the last couple of years.

		Industry Rank	Sector Rank
OM	3.42%
PM (TTM)	8.55%
GM	48.47%

OM growth 3Y-49.43%

OM growth 5Y-39.92%

PM growth 3YN/A

PM growth 5Y-27.27%

GM growth 3Y-3.56%

GM growth 5Y-6.14%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TARO is destroying value.

Compared to 1 year ago, TARO has about the same amount of shares outstanding.

Compared to 5 years ago, TARO has less shares outstanding

TARO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

TARO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	N/A

ROIC/WACC0.08

WACC9.43%

2.3 Liquidity

TARO has a Current Ratio of 3.61. This indicates that TARO is financially healthy and has no problem in meeting its short term obligations.

TARO has a Current ratio (3.61) which is comparable to the rest of the industry.

TARO has a Quick Ratio of 3.04. This indicates that TARO is financially healthy and has no problem in meeting its short term obligations.

With a Quick ratio value of 3.04, TARO perfoms like the industry average, outperforming 51.81% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.61
Quick Ratio	3.04

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TARO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 156.72%, which is quite impressive.

Measured over the past years, TARO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -24.80% on average per year.

Looking at the last year, TARO shows a quite strong growth in Revenue. The Revenue has grown by 9.81% in the last year.

TARO shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.25% yearly.

EPS 1Y (TTM)156.72%

EPS 3YN/A

EPS 5Y-24.8%

EPS Q2Q%122.22%

Revenue 1Y (TTM)9.81%

Revenue growth 3Y4.65%

Revenue growth 5Y-1.25%

Sales Q2Q%12.52%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 24.98, TARO is valued on the expensive side.

Based on the Price/Earnings ratio, TARO is valued cheaply inside the industry as 82.90% of the companies are valued more expensively.

The average S&P500 Price/Earnings ratio is at 29.63. TARO is around the same levels.

		Industry Rank	Sector Rank
PE	24.98
Fwd PE	N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TARO is valued cheaper than 96.37% of the companies in the same industry.

TARO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. TARO is cheaper than 83.42% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	22.96
EV/EBITDA	5.29

4.3 Compensation for Growth

TARO has a very decent profitability rating, which may justify a higher PE ratio.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TARO does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TARO PHARMACEUTICAL INDUS

NYSE:TARO (6/21/2024, 8:26:37 PM)

After market: 42.97 0 (0%)

42.97

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-20 2024-05-20/amc

Earnings (Next)07-24 2024-07-24/amc

Inst Owners1.69%

Inst Owner Change-100%

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap1.61B

Analysts43.33

Price Target43.86 (2.07%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)51.49%

Min EPS beat(2)26.5%

Max EPS beat(2)76.47%

EPS beat(4)4

Avg EPS beat(4)59.11%

Min EPS beat(4)26.5%

Max EPS beat(4)106.97%

EPS beat(8)4

Avg EPS beat(8)-3.86%

EPS beat(12)5

Avg EPS beat(12)-6.96%

EPS beat(16)6

Avg EPS beat(16)-80.87%

Revenue beat(2)1

Avg Revenue beat(2)1.54%

Min Revenue beat(2)-0.55%

Max Revenue beat(2)3.62%

Revenue beat(4)2

Avg Revenue beat(4)-0.56%

Min Revenue beat(4)-9.83%

Max Revenue beat(4)4.53%

Revenue beat(8)3

Avg Revenue beat(8)-5.15%

Revenue beat(12)4

Avg Revenue beat(12)-5.03%

Revenue beat(16)5

Avg Revenue beat(16)-5.45%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	24.98
Fwd PE	N/A
P/S	2.57
P/FCF	22.96
P/OCF	12.96
P/B	0.9
P/tB	0.91
EV/EBITDA	5.29

EPS(TTM)1.72

EY4%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)1.87

FCFY4.36%

OCF(TTM)3.31

OCFY7.71%

SpS16.74

BVpS47.71

TBVpS47.25

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	2.49%
ROE	3%
ROCE	1.19%
ROIC	0.79%
ROICexc	1.53%
ROICexgc	1.56%
OM	3.42%
PM (TTM)	8.55%
GM	48.47%
FCFM	11.18%

ROA(3y)2.12%

ROA(5y)0.14%

ROE(3y)2.63%

ROE(5y)-0.64%

ROIC(3y)2.06%

ROIC(5y)3.87%

ROICexc(3y)3.91%

ROICexc(5y)8.26%

ROICexgc(3y)4.17%

ROICexgc(5y)8.52%

ROCE(3y)3.12%

ROCE(5y)5.88%

ROICexcg growth 3Y-51.57%

ROICexcg growth 5Y-41.36%

ROICexc growth 3Y-51.56%

ROICexc growth 5Y-41.36%

OM growth 3Y-49.43%

OM growth 5Y-39.92%

PM growth 3YN/A

PM growth 5Y-27.27%

GM growth 3Y-3.56%

GM growth 5Y-6.14%

F-Score8

Asset Turnover0.29

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	174.37%
Cap/Sales	8.62%
Interest Coverage	250
Cash Conversion	236.87%
Profit Quality	130.77%
Current Ratio	3.61
Quick Ratio	3.04
Altman-Z	N/A

F-Score8

WACC9.43%

ROIC/WACC0.08

Cap/Depr(3y)221.93%

Cap/Depr(5y)174.21%

Cap/Sales(3y)10.63%

Cap/Sales(5y)7.89%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)156.72%

EPS 3YN/A

EPS 5Y-24.8%

EPS Q2Q%122.22%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)9.81%

Revenue growth 3Y4.65%

Revenue growth 5Y-1.25%

Sales Q2Q%12.52%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y20.73%

EBIT growth 3Y-47.08%

EBIT growth 5Y-40.67%

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y486.14%

FCF growth 3Y34.98%

FCF growth 5Y-24.83%

OCF growth 1Y291.68%

OCF growth 3Y39.58%

OCF growth 5Y-17.39%

TARO PHARMACEUTICAL INDUS (TARO) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens